RenovoRx completes enrollment in Phase III TIGeR-PaC pancreatic cancer trial
Reuters2026/08/11 12:30- RenovoRx completed patient enrollment in its Phase III TIGeR-PaC trial in locally advanced pancreatic cancer, moving the program into final follow-up.
- Results have not been presented; top-line data is expected in the second half of 2027 once the study reaches its required number of events.
- The trial tests whether targeted intra-arterial delivery of gemcitabine using the RenovoCath device can improve overall survival versus standard intravenous chemotherapy.
- RenovoCath is already FDA-cleared, positioning the readout as a key catalyst for broader adoption of the company’s drug-device treatment approach.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Delta Electronics (Thailand)'s Recent Selloff Presents Accumulation Opportunity -- Market Talk
The data center construction boom may increase inflationary pressure, and the Reserve Bank of Australia may be forced to maintain high interest rates.
The data center construction boom in Australia may lead to demand exceeding the supply capacity of the economy, which could push up inflation and force the Reserve Bank of Australia to maintain higher interest rates.
Reliance step-down unit Roptonal dissolves in Cyprus with effect Aug. 18, 2026
Crypto prices
More
